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Abstract: RNA interference (RNAi) is an efficient process of posttranscriptional gene silencing. In recent years it has 
been developed into a new technology in biopharmaceutical fields of science. RNAi products include short interference 
RNA (siRNA) but also short hairpin RNA (shRNA), bifunctional short hairpin RNA (bi-shRNA) and microRNA 
(miRNA). They combine with homologous fragments of the mRNA and cause its degradation. It results in inhibition of 
protein synthesis, or in mutation in the gene encoding it. RNAi has been used in analysis of genomes and creation of new 
animal models to test drugs. From the pharmaceutical point of view, what is the most important is its therapeutic applica-
tion. So far the basic and clinical research has been focused on the following targets: macular degeneration, cancer and an-
tiviral therapy. But there are also reports on clinical trials in asthma, hypercholesterolemia and genetic diseases such as 
inherited skin disorders and amyloidosis. Among over 20 therapeutics that reached clinical trials, only few are still inves-
tigated. Another few are clinical candidates. The review focuses on RNAi products under clinical evaluation and their 
most promising new applications. 
Keywords: Cancer, clinical trials, miRNA, post-transcriptional gene silencing, RNA interference, RNAi-based therapies, 
siRNA. 
INTRODUCTION 
The rapid development which has been visible in all 
fields of biology, particularly biochemistry and genetics, for 
several years now has produced successful results contribut-
ing to the explanation of a number of biological processes. 
One of the greatest achievements was the explanation of the 
mechanism of gene expression in eukaryotes and how this 
mechanism is controlled. This discovery, which has revolu-
tionized the research of gene expression, was RNA interfer-
ence (RNAi) [1]. The authors of this discovery - Andrew 
Fire and Craig Mello - were honored with the Nobel Prize in 
Medicine and Physiology in 2006. The results of their re-
search on the mechanism of RNA interference were pub-
lished in 1998 in Nature [2]. This discovery has opened new 
perspectives for researchers. It allows them to explore the 
gene function through the inhibition of gene expression. The 
phenomenon of RNA interference aroused the hopes of 
many biotechnological and pharmaceutical companies to 
develop a new generation of effective drugs, a personalized 
gene therapy for cancer among others. The aim of this re-
view was to present the newest information about RNAi 
therapeuticals which are currently in clinical trials. 
MECHANISM OF RNA INTERFERENCE ACTION 
The process of RNA interference was originally called 
PTGS - post-transcriptional gene silencing [3, 4]. However, 
 
*Address correspondence to this author at the Department of Technology 
and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University 
Medical College, 9 Medyczna Street, 30-688 Krakow, Poland; Tel: 0048 
126205598; Fax: 0048 126205405; E-mail: elzbieta.pekala@uj.edu.pl 
regardless of the name, this process enables the specific deg-
radation of target mRNA by using dsRNA (double-stranded 
RNA). It allows the inhibition of gene expression. 
RNAi plays a major role in regulating eukaryotic gene 
expression. There are two classes of particular interest 22-nt 
RNAs that can be further subdivided into siRNAs and miR-
NAs Fig. (1) siRNAs are double-stranded RNAs, which are 
transcribed endogenously or introduced into cells by viral 
infection or transfection [5]. 
siRNA pathway (step 1-7) Fig. (1): long double stranded 
RNA (dsRNA) as well as transcribed in the nucleus short 
hairpin RNA (shRNA) (1) are recognized and processed by 
Dicer, an RNase III enzyme, into duplexes of short interfer-
ing RNA (siRNA) of 21 to 24 nucleotides in length (2). Then 
endogenous siRNAs or synthetic siRNAs (3) can also be 
incorporated into the RNA-induced silencing complex 
(RISC) (4). A helicase in RISC unwinds the duplex siRNA 
(5), which then pairs to the target messenger RNAs 
(mRNAs) with a high degree of sequence complementarity 
to the siRNA (6). An unidentified RNase (Slicer) within 
RISC degrades the mRNA at sites not bound by the siRNA 
(7).  
miRNA pathway (step 8,9,2,4-6,10) Fig. (1): the genes 
encoding miRNAs are transcribed to produce the primary 
miRNA (pri-miRNA) (8). The dsRNA-specific ribonuclease 
digests the pri-miRNA in the nucleus to form another precur-
sor miRNA - pre-miRNA – which is exported to the cyto-
plasm (9). Like siRNAs, miRNAs are processed by Dicer 
creating the mature miRNA (2), one strand of which is in-
corporated into a ribonucleoprotein complex, which is simi-
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lar, if not identical, to RISC (4). It unwinds the duplex 
miRNA (5). Base pairing between the miRNA and its target 
(6) directs RISC to either destroy the mRNA or attenuate its 
translation into protein (10). 
The gene silencing process performed in insects and 
plants by endogenous siRNA may be divided into two 
stages. In the first stage, long, double-stranded RNA 
(dsRNA) is recognized and cleaved by cytoplasmic ribonu-
clease III (RNase III) - like protein known as Dicer, which is 
responsible for cleaving double stranded nucleic acid derived 
from replicating viruses [7, 8]. Short interfering double-
stranded siRNAs with a length from 19 to 25 base pairs (bp) 
are formed in the digestion process conducted by Dicer. 
Such siRNA has 3’-dinucleotide overhangs and 5’-phosphate 
groups [9]. 
In the second stage siRNA connects to the RISC (RNA-
induced silencing complex), where ATP-dependent helicase 
unwind the duplex. What is very important considering the 
gene therapy, synthetic siRNA introduced into cells can be 
also incorporated into the RISC complex. The RNA helicase 
activity of the RISC complex untangles siRNA to single-
stranded form, and removes one of the strand [10]. The sin-
gle siRNA strand located in the RISC (guide strand) is used 
to find complementary mRNA sequences in the cytoplasm. 
Ago2 protein (Argonaut family) is responsible for the 
hydrolysis of phosphodiester bond in mRNA 
(complementary to the guide strand in RISC complex) [11]. 
to the guide strand in RISC complex) [11]. siRNA is able to 
cleave target RNA in both the cytoplasm and the nucleus. It 
was shown that the established, active RISC complex does 
not dissociate after hydrolysis of one molecule of mRNA, 
but catalyzes the subsequent reaction, which contributes to 
the high efficiency of RNAi mechanism [12]. 
Another RNAi is shRNA. shRNA is a molecule which 
has a short loop sequence between the two complementary 
strands. The expressed shRNA is exported into the cyto-
plasm where it is processed by Dicer into siRNA [13]. 
miRNAs are also a member of the RNAi family. The 
naturally occurring miRNAs are synthesized in the nucleus 
in large precursor forms. The enzyme known as Drosha me-
diates the processing of the primary miRNA transcripts into 
pre-miRNAs, which are then exported to the cytoplasm [14]. 
Mature miRNAs are dependent on Dicer for appropriate 
processing and are incorporated into a ribonucleoprotein 
complex (like siRNA). The differences between the siRNA 
and the miRNA are that miRNA is endogenous to every cell 
and it binds to its target, but – unlike siRNA – the comple-
mentary is not 100%. Moreover, miRNA causes the transla-
tional inhibition of the target mRNA, while siRNA cleaves it 
[15].  
A novel technology exploiting both the cleavage and the 
translational inhibition has been described. It is called bi-
functional shRNA. The bi-functional concept is to design 
 
 
Fig. (1). Mechanism of siRNA and miRNA action [5,6]. 
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one bi-shRNA with two stem-loop shRNAs for each targeted 
mRNA - one stem-loop shRNA structure with a perfect 
match and one with mismatches at the central location. The 
“bi-functional” shRNA, by virtue of loading onto multiple 
types of RISCs - both cleavage-dependent RISC (fully 
matched shRNA) and cleavage-independent RISC (mis-
matched shRNA) - is able to simultaneously induce degrada-
tion of target mRNA and also inhibit translation through 
mRNA sequestration. Compared to siRNA or miRNA, it 
leads to a more rapid onset of gene silencing, greater durabil-
ity and higher efficacy [16, 17]. 
The RNAi-based mechanism is involved in many physio-
logical processes in a wide range of species. For example, in 
Caenorhabditis elegans and Drosophila melanogaster RNAi 
controls transposons [18, 19], in yeast RNA interference is 
involved in heterochromatin formation [20, 21], in plants it is 
used as a defense against viral infection [22]. Regardless of 
the function which RNAi plays in organisms, it can be used 
to alter gene expression. These small molecules may be used 
to shut down the activity of mutant genes, which contributes 
to the cure of many diseases.  
The discovery of RNA interference made it possible to 
acquire another tool for gene therapy. The research con-
ducted in this area offers the hope that RNAi molecules will 
be much more effective in gene therapy than molecules used 
so far, like chemically modified antisense oligonucleotides 
(AON) [23], or ribozymes [24]. Most comparative studies 
have already demonstrated that the effect of siRNA lasts 
longer than the effect after the administration with AON or 
ribozymes [10]. In contrast to drugs based on antisense nu-
cleotides, siRNA molecules can cleave not only one individ-
ual mRNA. One molecule of siRNA causes the degradation 
of many molecules of the messenger RNA. Low concentra-
tion of siRNA, which is needed to elicit a positive effect and 
the fact that siRNA rapidly and specifically associates with 
RISC, reduce the binding of siRNA to other cellular proteins 
[25]. Introducing synthetic siRNAs in nanomolar concentra-
tions can cause an effective downregulation in the expression 
of the target mRNA [26].  
POTENTIAL SIDE EFFECTS 
To be effective as a medicine, RNAi cannot cause any ef-
fects, except those which are associated with silencing of the 
target gene. This issue is particularly important in therapeutic 
applications where side effects are very undesirable. The 
sources of these adverse effects are non-specific silencing of 
genes, so called off-target silencing [27, 28] and the fact that 
siRNAs longer than 30bp trigger the interferon pathway [29]. 
This induction of secretion interferon is due to the innate 
immune system. Our organism, which recognizes long 
dsRNA as a virus particle, “thinks that something is wrong” 
and tries to overcome the infection [30]. To avoid this prob-
lem scientists need to use particles with a length of 21-23 bp 
[29]. Another problem is the fact that gene silencing by 
transfection the mammalian cells with siRNA is not stable 
and long lasting (like in Caenorhabditis elegans [31]) but is 
transient. To overcome this problem RNAi can be introduced 
into mammalian cells by vector systems in two types: 
shRNAs – hairpin type where sense and antisense strands are 
expressed by one polymerase III promoters [32] or by Tan-
dem type where sense and antisense strands are expressed by 
two separate polymerase III promoters and the strands anneal 
inside the cells. In both cases the molecules are converted 
into siRNA by using cellular machinery - Dicer [33, 34]. 
According to Miyagishi [35] shRNA – type is a more potent 
silencer of gene expression. Nowadays actually not polym-
erase III but polymerase II is used to construct a gene ex-
pression system for in vivo and in vitro applications. It is due 
to the fact that polymerase III lacks control of spatial and 
temporal gene expression and can compete for and occupy 
endogenous nuclear export mechanism [36]. There are sev-
eral ways to obtain siRNA, for example chemical synthesis 
[37], enzymatic cleavage [38], cloning of sequence coding 
antisense RNA into plasmid, transfection and expression in 
cells [39] or cloning into adenoviral [40], lentiviral [41] or 
retroviral vectors [42]. Transfection can be performed either 
by electroporation [43] or by lipid-based formulations [44]. 
THE SPECTRUM OF THE USE OF RNAi IN VARI-
OUS DISEASES 
RNA interference is used for the knockdown of gene ex-
pression in animals and promises to provide a quicker and 
cheaper way to generate knockout animals which are now an 
invaluable source of knowledge as models of disease [45]. 
RNAi was first used to treat hepatitis in the mouse liver [46]. 
A year later, the Food and Drug Administration approved the 
first clinical trials using RNA interference. There have been 
many studies in different systems in order to use RNAi to 
treat a bunch of different diseases. Currently the studies are 
related to the treatment of wet AMD (age-related macular 
degeneration), the major cause of blindness in the United 
States in patients over the age of 55. The goal of this thera-
pies is inhibiting VEGF (Vascular Endothelial Growth Fac-
tor) [47]. After some setbacks – with AGN211745 (Ranibi-
zumab) which did not pass Phase II trials – Cand5 is the 
siRNA currently in Phase II trials for use in AMD and also 
diabetic macular degeneration [48].  
siRNA can be also used as a new antiviral therapy [49, 
50]. In the case of HIV - CCR5 was silenced by transduction 
the cells with lentiviral vector with shRNA recognizing 
CCR5. This RNAi procedure had no side effects and resulted 
in the prevention of viral entry into human peripheral blood 
lymphocytes [51, 52]. Also in the case of hepatitis B, trans-
fection of siRNA into HepG2.2.15 cells, which constitutively 
produce HBV particles, caused a significant reduction in 
viral RNA production [53]. Another therapeutic agent - PF-
05095808 – has an antiviral activity against chronic hepatitis 
C virus. PF-05095808 comprises a recombinant adeno-
associated virus (AAV) DNA vector which directs expres-
sion of three shRNAs targeted to conserved regions of the 
HCV genome [54]. 
siRNA appears also to be ideal for inhibiting influenza 
virus infection [55]. The influenza virus is an RNA virus, 
without any DNA intermediates during its entire life cycle, 
and its genome encodes only 10 proteins. Each of these pro-
teins plays a critical role during the virus life cycle. Interfer-
ence with the production of any one of them is likely to have 
severe consequences on viral replication and production [56, 
57]. Unfortunately, up to date scientists have not managed to 
create siRNA which eliminates the influenza problem. 
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Probably the reason for this issue is viral escape. Viral repli-
cation can be blocked efficiently at the beginning, but after a 
while the virus titer increases again, because of the selection 
of mutants which can overcome the inhibition. The solution 
to this problem could be siRNA which targets strongly con-
served regions of the virus. 
siRNA can also be used as a tool to fight parasites. For 
example, silencing PP1 serine/threonine protein phosphatase 
by using RNAi could disrupt the life cycle of Plasmodium 
falciparum – the causative agent of malaria [58]. 
There are also attempts to use RNAi in diseases in which 
there is no viable pharmaceutical treatment option so that 
surgical intervention is the first-line treatment. An example 
of such a disease is a Familial Adenomatous Polyposis 
(FAP). In classical FAP -catenin gene is known to be dys-
regulated. CEQ508 drug candidate (Marina Biotech) is a live 
attenuated Escherichia coli engineered to enter into dysplas-
tic tissue and release a payload of shRNA to silence 
catenin expression. CEQ508 has been shown in the non-
clinical setting to reduce the amount of intracellular -
catenin.  
RNAi can also be used in inherited metabolic disorders 
like mucopolisaccharidoses (MPS). Mucopolysaccharidoses 
are caused by the absence or malfunctioning of lysosomal 
enzymes needed to break down molecules called glycosami-
noglycans (gag). The buildup of undegraded heparan gag in 
the brain cells of affected MPS children results in a progres-
sive neurological deterioration. One approach is substrate 
deprivation therapy (SDT), which acts by inhibiting the syn-
thesis of the substrate for the missing enzyme [59]. Unfortu-
nately chemical SDT agents tested reduce the synthesis of all 
gag type. The RNA interference technology is one way of 
specifically targeting the synthesis of an individual gag type 
by reducing the expression of one or more of the glycosyl 
transferases responsible for gag synthesis - only these gag 
types that are involved in a specific MPS disorder. One of 
such gag types is heparan sulphate. EXTL2 and EXTL3 are 
the enzymes involved in heparan sulphare synthesis. RNAi 
was used by Kaidonis et al. to specifically target EXTL2 and 
EXTL3 expression. All shRNAs directed at EXTL2 signifi-
cantly decreased gag synthesis in an MPS cell lines [60]. In 
another study [61] the mRNA levels of genes XYLT1, 
XYLT2, GALTI and GALTII were reduced by the use of 
siRNA. The products of these genes are involved in gag syn-
thesis. It showed the feasibility of using the RNAi approach 
in reducing the buildup of tissue gag characteristic of MPS 
disorders. What is interesting, Dziedzic et al. showed that 
using two siRNAs is generally more effective than using 
single siRNA, but the differences were not statistically sig-
nificant. Therefore the potential benefit from the use of two 
siRNAs over the use of a single siRNA is doubtful in the 
light of the cost-benefit ratio and possibly stronger side-
effects of the putative therapy [62]. 
RNAi AGAINST CANCER 
RNA interference due to its specificity and breadth of 
targeting capability could be used as a therapeutic weapon in 
a number of diseases. Cancers are not an exception. A large 
number of preclinical studies have presented favorable out-
comes by silencing genes critical for tumor cell growth, me-
tastasis, angiogenesis and chemoresistance. 
Lung cancer is a worldwide leading cause of death [63]. 
Patients with non-small-cell-lung cancer (NSCLC) are gen-
erally non-responsive to initial chemotherapy and despite 
extensive research efforts in screening, diagnostics and 
therapeutics, prognosis for suffering patients is still poor and 
only 8-14% of them survive more than 5 years from the time 
of diagnosis [64]. Because the tumor invasion and metastasis 
are characteristic for the aggressive phenotype of human 
cancers [65], finding a blocking factor of these stages of tu-
mor development could facilitate the design of anticancer 
drugs. When it comes to NSCLC, VEGF-C appears to be a 
factor involved in the crucial stages of development and pro-
gression of cancer [66]. It was found that using siRNA 
against VEGF-C suppresses tumor cell growth, invasion and 
migration in vitro. And using lentivirus encoded shRNA 
against VEGF-C suppresses tumor cell growth, angiogenesis 
and lymphangiogenesis in vivo [67]. Using such a RNAi 
downregulates the chemokine receptors CXCR4 and CCR7 
[67] which are highly expressed in many kinds of tumors and 
may be involved in metastatic process [68, 69]. Silencing of 
VEGF-C also trapped VEGFR-3 [67] which in cancer cells 
promotes motility and invasion both in vitro and in vivo [68]. 
These findings suggest that siRNA targeting of VEGF-C can 
be an effective therapeutic strategy for non-small-cell lung 
cancer [70]. 
Another target for RNAi in NSCLC could be Nrf2 [Nu-
clear factor (erythroid-derived 2)-like 2]. This transcription 
factor activates cytoprotective pathways against oxidative 
injury and apoptosis. It also has the ability to regulate the 
expression of electrophile and xenobiotic detoxification en-
zymes as well as efflux proteins [71]. The activity of Nrf2 is 
increased in NSCLC cells due to the mutations in Nrf2 in-
hibitor – Keap1 [72]. Loss of Keap1 activity leads to consti-
tutive activation of Nrf2 in lung cancer cells, which upregu-
lates the expression of antioxidants, electrophile and drug 
detoxification enzymes and leads to the protection of cancer 
cells [73]. shRNA targeting the 3’ end of the Nrf2 transcript 
is able to lower the Nrf2 protein level. It induces generation 
of reactive oxygen species (ROS), suppresses tumor growth 
and results in increased sensitivity to chemotherapeutic drugs 
which induces cell death [74]. The downregulation of 
multidrug resistance protein like ATP-binding cassette by 
shRNA targeting Nrf2 is especially important in cancers with 
chemoresistance, like NSCLC, and it was proven [74] that 
such RNAi increased drug accumulation and enhanced che-
mosensitivity in cancer cells.  
Sensitizing cells to apoptosis can also be achieved by si-
lencing the inhibitors of this process, like Apollon, which is 
a member of the inhibitors of apoptosis protein (IAP) family 
[75]. It is known that this protein is upregulated in brain tu-
mor such as glioma [76] and in acute myeloid leukemia [77]. 
The effects of Apollon knockdown, accomplished through 
RNA interference, were also examined for breast cancer. 
Apollon-specific siRNA was able to downregulate the in 
vitro proliferative potential of breast cancer cells. This RNAi 
has also the ability to induce the apoptosis in the cells men-
tioned [78]. These data suggests the opportunity to conduct a 
survey in which the tumor with overexpression of Apollon 
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will be selected and treated with siRNA against this IAP. In 
this type of treatment using RNAi could bring a powerful 
tool in the fight against cancer. 
Another regulator of apoptosis is type VI intermediate 
filament protein – Nestin [79]. It was shown that Nestin 
plays an important role in the promotion of cell proliferation 
[80]. Moreover, this protein exhibits cytoprotective functions 
in neural stem cells wherein it prevents Cdk5-dependent 
apoptosis by the sequestering of Cdk5/p35 complexes [81]. 
Increased Nestin expression has been reported in various 
tumor cells, for example pancreatic ductal adenocarcinoma 
(PDAC) [82]. The fact that scientists in recent years are more 
and more interested in angiogenesis is not surprising when 
we consider angiogenesis as an attractive target for cancer 
therapy. Recently, the correlation between Nestin, angio-
genesis and PDAC has been established. It was shown that 
Nestin may be a useful marker of newly-formed blood ves-
sels in tumor tissues. Reduced Nestin expression – using the 
siRNA - affects the growth and migration activities of vascu-
lar endothelial cells. The inhibition of tumor growth was also 
indicated in vivo after using RNAi (anti-angiogenic effects 
on mouse’s tumor vessels were shown) [83]. 
The effectiveness of anti-angiogenic agents for cancer 
treatment has been reported, and Nestin is not the only thera-
peutic target that can be silenced using RNAi to obtain 
downregulation of formation of new blood vessels from pre-
existing vessels. The most critical pro-angiogenic factor is 
the vascular endothelial growth factor. Rho GTPases are 
small molecule members of the Ras superfamily of small 
GTPases which function as molecular switches in the cell. It 
was shown that Rac1 is an important regulator of VEGF-
mediated angiogenesis [84]. Moreover, silencing of Rac1 
using siRNA inhibited VEGF-mediated tube formation both 
in vitro and in vivo [85]. Another reason why Rac1 could be 
a good therapeutic target for RNAi in cancers is the fact that 
Rac1 in cancer cells is overexpressed and its activity is in-
creased [86]. Rac1 silencing using siRNA inhibits VEGF-
induced migration, invasion and proliferation of HUVECs 
(Human Umbilical Vein Endothelial Cells). This proves that 
inhibition of Rac1 using RNA interference is an effective 
tool for inhibiting angiogenesis and tumor growth.  
Oncogenes expressed at abnormally high levels are also 
attractive targets for RNAi-based therapies against cancers. 
In ovarian cancer cells the tyrosine kinase receptor EphA2 
gene is overexpressed, which is associated with poor clinical 
outcome. EphA2 can function as an oncoprotein which can 
be an ideal therapeutic target because its downregulation 
reduces tumorigenicity in preclinical studies of breast and 
pancreatic cancer [87, 88]. After the delivery of siRNAs up 
to 50% reduction of tumor size was observed. Moreover, 
when RNAi therapy was combined with paclitaxel, up to 
90% reduction in tumor size was observed [89]. The clinical 
study on safety and the highest tolerable dose of siRNA-
EphA2-DOP was started in May 2012. 
RNAi IN CLINICS 
The use of siRNA is not limited only to the laboratories. 
The first clinical applications of RNAi were directed against 
AMD, Parkinson’s disease and amyothrophic lateral sclero-
sis [90], and although some of the clinical trials of siRNA 
were suspended - for example studies on Ranibizumab [91] - 
it is not difficult to find examples of RNAi which are cur-
rently in clinical trials (Tables 1, 2). Below we present some 
of them. 
NON-CANCER RNAi-BASED THERAPIES UNDER-
GOING CLINICAL TRIALS 
TD101 
Pachyonychia congenital (PC) is an autosomal dominant 
skin disorder, which affects an estimated 550 patients 
worldwide. Pathogenic mutations in keratin K6a, K6b, K16 
or K17 act via a dominant negative mechanism, leading to 
manifestations of the disease. Patients with PC suffer from 
painful plantar blistering and keratoderma that requires usage 
of ambulation devices. Current treatment is limited to me-
chanical removal of the thick calluses, non-specific topical 
keratolytics, and oral retinoids. None of this is satisfactory. 
TransDerm Company designed siRNA for treatment of 
Pachyonychia Congenita – TD101, which is also the first 
siRNA-based therapeutic for skin. TD101 targets a single 
nucleotide mutation – K6a. Because of this, it will only be 
effective against PC subjects harboring this specific muta-
tion, but with little or no effect on wild-type expression [92]. 
There are currently only six known patients who carry this 
mutation in the International Pachyonychia Congenita Re-
search Registry. Phase Ib clinical trial to test the safety and 
efficacy of TD101 was evaluated in a single patient 
(woman), who is the only adult in the US known to have the 
particular mutation (K6a N171K mutant) that the drug tar-
gets. Two children of this woman also suffer from PC. It was 
decided that the treatment of the adult patient will be com-
pleted prior to the recruitment of the minors. The patient 
received TD101 twice a week for 17 weeks. During this time 
the dosage of the drug was increased steadily. Randomly 
assigned solutions of TD101 or vehicle control were injected 
in symmetric plantar calluses on opposite feet. During the 
first 2 months of the trial, no dramatic differences (subjective 
or objective) between feet were noted by either the patient or 
physician. On approximately day 70 of the trial the patient’s 
subjective evaluation of the injected callus began to indicate 
a marked difference in the right foot, but no change in the 
left foot. On day 98 of the trial the callus at the site of injec-
tion on the right foot began to fall away and revealed healthy 
skin. Subjective and objective changes in the right foot be-
gan returning toward baseline after the drug was discontin-
ued and reached baseline ~30–50 days after the last dose. No 
adverse events occurred during the trial or in the 3-month 
washout period. Subjective patient assessment and physician 
clinical efficacy measures revealed regression of callus on 
the siRNA-treated, but not on the vehicle-treated foot. The 
degree of pain experienced by the patient at the time of injec-
tion is a significant concern. Future efforts must focus on 
improved delivery methods for TD101, such as pharmaceuti-
cal formulations for noninvasive topical delivery (like 
cream) [93, 94]. According to the Mary Schwartz, director of 
the PC project (the non-profit organization funding the 
drug’s clinical development), TD101 will be tested in addi-
tional PC patients in Ireland.  
TKM-Ebola1 
The Zaire species of Ebola virus (ZEBOV) is associated 
with periodic outbreaks of hemorrhagic fever in human
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Table 1. RNAi-Based Other Than Cancer Therapies Undergoing Clinical Trials 
Name of the  
Molecule 
Disease Stage Features 
Government Identifier 
[90] Or References 
TD101 Pachyonychia Congenita Phase I trial 
siRNA targeting a K6a – one of the keratins 
mutated in PC 
NCT00716014 
TKM-Ebola Ebola infection Phase I trial 
siRNA targeting viral RNA; delivered by 
SNALP liposome 
NCT01518881 
RXI-109 Dermal scarring Phase I trial 
RNAi targeting connective tissue growth 
factor (CTGF); delivered by intradermal 
needle injection 
NCT01640912 
SYL040012 Intraocular pressure and glaucoma Phase II trial 
siRNA administered topically to treat ocular 
hypertension associated with open-angle 
glaucoma 
NCT00990743 
ALN-PCS02 Hypercholesterolemia Phase I trial 
SNALP-formulated RNAi targeting PCSK9 
what results in lower LDL cholesterol level 
NCT01437059 
ALN-RSV01 RSV infection Phase II trial 
siRNA targeting respiratory syncytial virus 
replication 
NCT01065935 
ALN-TTR02 TTR - mediated Amyloidosis Phase II trial siRNA targeting transthyretin NCT01617967 
Bevasiranib 
(Cand5) 
Wet Age-Related Macular Degen-
eration 
Phase II trial 
siRNA silencing VEGF; the target population 
are patients with diabetic macular edema 
NCT00306904 
 
Table 2. RNAi-Based Cancer Therapies Undergoing Clinical Trials 
Name of the Mole-
cule 
Disease Stage Features 
Government Identifier 
[90] Or Reference 
CALAA-01 
Nonresectable or metastatic solid 
tumors 
Phase I trial 
siRNA against M2 subunit of ribonucleotide 
reductase in nanoparticles; causes antiprolif-
erative effects 
NCT00689065 [91] 
Atu027 Solid tumors Phase I trial 
siRNA targeting Protein Kinase N3 gene ex-
pression in the vascular endothelium 
NCT00938574 [92] 
ALN-VSP02 
Liver cancer, cancer with liver 
involvement 
Phase I trial 
SNALP formulation; dual-targeted RNAi 
drug: anti-angiogenic mechanism (anti VEGF), 
anti-proliferative mechnism (anti KSP) 
NCT00882180 
siRNA-EphA2-DOP Advanced Cancers Phase I trial 
siRNA targeting EphA2 gene using neutral 
liposomal delivery 
NCT01591356 
TKM-PLK1 
Primary or Secondary Liver Can-
cer 
Phase I trial 
Lipid nanoparticles containing siRNA against 
the PLK1 gene product 
NCT01262235 
SPC2996 
Chronic lymphocytic leukemia 
(CLL) 
Phase II trial 
Antisense molecule targeting the mRNA of the 
Bcl-2 oncoprotein; causes immunostimulatory 
effects 
NCT00285103 [93] 
FANGTM Vaccine Advanced Solid Tumors Phase I trial 
Plasmid encoding GMCSF and bi-shRNA 
designed to indirectly reduce levels of TGF  
isoforms by targeting furin convertase 
NCT01061840 [94] 
FANGTM Vaccine 
High Risk Stage IIIc Ovarian 
Cancer 
Phase II trial 
Plasmid encoding GMCSF and bi-shRNA 
designed to indirectly reduce levels of TGF  
isoforms by targeting furin convertase 
NCT01309230 
FANGTM Vaccine Advanced Melanoma Phase II trial 
Plasmid encoding GMCSF and bi-shRNA 
designed to indirectly reduce levels of TGF  
isoforms by targeting furin convertase 
NCT01453361 
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(Table 2) contd…. 
Name of the Mole-
cule 
Disease Stage Features 
Government Identifier 
[90] Or Reference 
FANGTM Vaccine Colorectal Cancer Phase II trial 
Plasmid encoding GMCSF and bi-shRNA 
designed to indirectly reduce levels of TGF  
isoforms by targeting furin convertase 
NCT01505166 
siG12D LODER 
Unresectable Locally Advanced 
Pancreatic Cancer 
Phase II trial 
Miniature biodegradable polymeric matrix 
containing siRNA for the mutated KRAS 
oncogene 
NCT01676259 
 
populations with mortality rates reaching 90%. The first out-
break occurred on 26 August 1976 in Yambuku. Unfortu-
nately, there is currently no FDA-approved ebolavirus-
specific therapy for Ebola virus disease [95]. Ebola virus 
genome contains, among others, the L protein-coding genes 
and VP35 which make up the polymerase complex. The po-
lymerase complex is responsible for the transcription and 
replication process of the Ebola virus genome. The L protein 
seems to be an ideal target for antiviral interventions. Its 
suppression should lead to a nearly complete loss of all RNA 
synthesis. Moreover, there are no similar proteins in mam-
malian cells [96].  
In February 2012 TKM-Ebola Phase I clinical trial was 
initiated. This RNAi therapeutic was invented by Tekmira 
Pharmaceuticals Corporation. TKM-Ebola is delivered using 
Tekmira's lipid nanoparticle (LNP) delivery technology. 
LNP platform is being utilized in multiple clinical trials by 
both Tekmira and its partners. In this technology siRNA is 
encapsulated with high efficiency in uniform lipid nanoparti-
cles that are effective in delivering RNAi therapeutics to 
disease sites in numerous preclinical models. LNP-based 
products have been reviewed by multiple FDA divisions for 
use in clinical trials. 
The objective of the Phase I trial is to assess the safety 
and tolerability of TKM-Ebola and evaluate the pharmacoki-
netics and systemic exposure following both a single-
ascending dose and multiple-ascending doses of TKM-
Ebola. During this trial specific FDA regulatory guidelines 
called the “Animal Rule” will be used. “Animal rule” is a 
path to drug approval for life-threatening agents where hu-
man efficacy trials aren't ethical or feasible [97].  
RXI-109 
Dermal wound healing is a complex process that, when 
properly orchestrated, leads to re-establishment of skin integ-
rity with minimal residual scarring. Hypertrophic scars, 
which are an outcome of burns or surgery, represent an ex-
ample of pathologic dermal scarring. They can be character-
ized by a diverse spectrum of disorders like unsightly scars, 
keloids or even life-threatening systemic diseases such as 
scleroderma. Over-expression of connective tissue growth 
factor (CTGF) mRNA and protein has been observed in 
chronic fibrotic disorders affecting multiple organ systems. 
Although CTGF has minimal basal expression in the normal 
skin, it demonstrates transient up-regulation for several days 
following dermal injury. Persistent over-expression of CTGF 
has been observed in biopsies of keloids and localized scle-
rosis. Therefore CTGF, as a one of the key regulator of scar-
ring, may be an attractive target for scar prevention [98]. 
 RXI-109 was designed by RXi Pharmaceuticals to re-
duce or prevent skin scarring following trauma or surgery 
and is intended to reduce disfiguring hypertrophic scarring 
and keloids. This RNAi compound has been shown to effec-
tively silence CTGF in vitro in cell culture and in vivo in 
rodent skin models. In July 2012 Phase I clinical trial on 
RXI-109 was initiated. The primary purpose of that study is 
to evaluate the safety and tolerability of a single intradermal 
administration of RXI-109 at small surgical incisions in the 
abdominal skin that will later be removed during an elective 
abdominoplasty. The effect of RXI-109 versus placebo on 
scarring at these incision sites will be evaluated visually and 
histologically [99]. In September 2012 RXi Pharmaceuticals 
Corporation announced that RXI-109 was well tolerated by 
intradermal injection. No serious local or systemic side ef-
fects were observed in the subjects at any of the doses ad-
ministered. Local erythema (redness) around the injection 
site was somewhat more pronounced in the cohort that re-
ceived the highest dose, but these instances of redness disap-
peared usually within 72 hours after the injection, and did 
not give rise to significant subjective complaints from the 
study subjects [100]. 
SYL040012 
Glaucoma is a group of progressive optic neuropathies. 
Without adequate treatment, glaucoma can progress to irre-
versible visual disability and eventual blindness [101]. Of the 
many types of glaucoma, primary open angle glaucoma 
(POAG) is perhaps the most common. In most cases of 
POAG, increased resistance to the outflow of aqueous humor 
results in a rise in intraocular pressure (IOP), which eventu-
ally leads to loss of retinal ganglion cells. New siRNA in-
vented in Sylentis biopharmaceutical company - SYL040012 
has proven to be effective in vivo when administered topi-
cally to treat ocular hypertension associated with open-angle 
glaucoma. These trials showed that pretreatment with 
SYL040012 prevents the induced increase in intraocular 
pressure in this ocular hypertension model. The prophylactic 
effect of this compound is greater than the one described 
previously in this model with the drugs currently used for 
treating glaucoma, such as timolol or Xalatan. The results of 
the Phase I trial were presented at the 7th Conference of the 
Spanish Society for Glaucoma, in Alicante. The Phase I trial 
endpoint was to determine the tolerance and safety of 
SYL040012 ophthalmic drops. It was administered to 30 
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healthy volunteers aged 18 to 33. Patients showed excellent 
local and systemic tolerance to SYL040012, leading to very 
positive trial results. On 13 June 2012 Sylentis has received 
authorization from the Spanish and Estonian regulatory 
agencies to commence Phase II clinical trials with 
SYL040012 for treating ocular hypertension associated with 
glaucoma. The endpoint of this trial is to evaluate the effect 
of a range of doses of the drug on 80 patients with ocular 
hypertension or glaucoma in the three countries [102]. 
ALN-PCS02 
Coronary artery disease is the leading cause of death in 
the U.S. Most forms of hypercholesterolemia can be treated 
through statins. However, there are patient populations that 
are statin intolerant or statin resistant. After 2003 proprotein 
convertase subtilisn/kexin type 9 (PCSK9), which is one of 
the serine proteases, has emerged as a novel target to lower 
low-density lipoprotein (LDL) cholesterol levels. PCSK9 
binds to hepatic LDL receptors and targets them for degrada-
tion. This process reduces the capacity of the liver to bind 
and remove LDL cholesterol and results in increased LDL 
cholesterol levels. Some patients with low levels of LDL 
cholesterol had PCSK9 loss-of-function mutations and these 
patients had a reduced incidence of coronary heart disease. 
These studies raised the possibility that inhibition of PCSK9 
or its mRNA might lower LDL cholesterol levels in patients 
with hypercholesterolemia [103]. Alnylam Pharmaceuticals 
develops ALN-PCS02 – a RNAi therapeutic for the treat-
ment of hypercholesterolemia, or high levels of cholesterol 
in the blood. This RNAi therapeutic targets the gene PCSK9 
and has the potential to lower tissue and circulating PCSK9 
levels resulting in higher LDL receptor levels in the liver, 
and subsequently lower LDL cholesterol levels. 
Pre-clinical data with ALN-PCS02 have shown specific 
silencing of PCSK9 mRNA and PCSK9 serum protein levels 
of up to 90%. These studies have also demonstrated a greater 
than 50% reduction in the levels of LDL, which is rapid and 
durable, lasting for weeks after a single dose. Positive results 
from the Phase I trial were presented in April 2012. These 
results showed that ALN-PCS02, in the absence of concomi-
tant lipid-lowering agents such as statins, resulted in statisti-
cally significant and durable reductions of PCSK9 plasma 
levels of up to 84% and lowering of LDL up to 50%. ALN-
PCS02 was shown to be safe and well tolerated. Moreover, 
there were no serious adverse events related to study drug 
administration [104]. 
ALN-RSV01 
Human respiratory syncytial virus (RSV) is a ubiquitous 
virus and the most common cause of serious lower respira-
tory tract infections in infants and young children worldwide, 
as well as an important pathogen in elderly individuals and 
immunocompromised patients [105]. Despite nearly four 
decades of research, no RSV vaccine approach has been suc-
cessful at conferring protection at a level that exceeds the 
incomplete protection afforded by natural infection. Cur-
rently, the only antiviral approved for use for the treatment 
of RSV infection is ribavirin, but due to its teratogenicity, 
limited efficacy, and poorly understood mechanism of ac-
tion, it has very limited use [106]. The N, P, and L proteins 
are contained within the nucleocapsid of the virion and are 
required for various steps within the replication cycle. Con-
sistent with their absence from the outer virus surface, the 
RNAs encoding the N, P, and L proteins are among the most 
highly conserved regions of the RSV genome. Therefore, 
screening of siRNAs targeting the mRNAs for this proteins 
would result in the selection of the most potent and broad-
spectrum inhibitors of viral replication [107]. Alnylam 
Pharmaceuticals RNAi therapeutic - ALN-RSV01 - was de-
signed to target the nucleocapsid N gene of the RSV genome 
because, as mentioned, this nucleocapsid gene is critical to 
viral replication. ALN-RSV01 has shown a robust antiviral 
effect in vitro against RSV [108].  
In Phase I trial ALN-RSV01 has been shown to be safe 
and well tolerated [109]. In Phase II trial in experimentally 
infected adults, intranasal ALN-RSV01 reduced the rate of 
RSV infection by 44% [104, 110, 111]. In September 2012 
complete results from Phase IIb trial were reported. It was 
shown that treatment with ALN-RSV01 gave an over eight-
fold reduced risk in developing progressive bronchiolitis 
obliterans syndrome (BOS) at 180 days after RSV infection. 
Alnylam Pharmaceuticals plans to meet with U.S. and Euro-
pean regulatory authorities to determine next steps for this 
program [104, 112]. 
ALN-TTR02 
RNAi gives hope also for patients with orphan diseases. 
Transthyretin-mediated amyloidosis (ATTR) is one of such 
diseases. ATTR is caused by mutations in the transthyretin 
(TTR) gene, which is expressed predominantly in the liver. 
This mutation results in the accumulation of toxic deposits of 
the misfolded protein in several tissues including nerves, 
heart, and gastrointestinal tract. Liver transplantation is the 
only treatment option for ATTR, but this invasive procedure 
is not available for most ATTR patients, whose life expec-
tancy is from five to fifteen years from the onset of the dis-
ease. The Alnylam Pharmaceuticals designed ALN-TTR02 - 
a siRNA which specifically inhibits TTR mRNA, thereby 
reducing the accumulation of TTR protein. In July 2012 
Alnylam Pharmaceuticals announced the achievement of 
positive clinical results from Phase I trial with ALN-TTR02: 
up to 94% reduction of serum TTR and a nearly 80% level of 
suppression sustained at one month with just a single dose. 
In June 2012 Phase II study of ALN-TTR02 (evaluating 
clinical activity, safety, and tolerability) was initiated in 
ATTR patients [104].  
Bevasiranib (Cand5) 
Diabetic macular edema (DME) is the leading cause of 
vision loss in diabetic retinopathy. DME is the result of the 
breakdown of the retinal capillary endothelium in patients 
with diabetes mellitus (Type I and II) and the critical mole-
cule involved in the pathogenesis of neovascular eye dis-
eases – like DME – is VEGF. The majority of antiangiogenic 
agents with evidence of clinical efficacy at this time gener-
ally act by inhibiting VEGF. Anti-VEGF therapies have been 
shown to be remarkably effective in preventing vision loss 
from the neovascular and exudative complications of retinal 
diseases. Bevasiranib (Acuity Pharmaceuticals) is a siRNA 
molecule which targets the messenger RNA of the VEGF 
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protein. This RNAi therapeutical, known previously as 
Cand5, after intravitreal injection is well distributed within 
the eye and localizes to the retina [113, 114]. Cand5 showed 
in Phase I clinical studies to be safe and well tolerated in 
patients with DME. The purpose of Phase II study is to 
evaluate the pharmacokinetics, safety and preliminary effi-
cacy of 3 doses of Cand5. 
RNAi-BASED CANCER THERAPIES UNDERGOING 
CLINICAL TRIALS 
RNA interference due to its specificity and adaptability 
has great potential to serve as a personalized gene therapy 
against cancer. The use of RNAi may lead to downregulation 
of metastasis, angiogenesis and chemoresistance as well as 
upregulation the apoptosis. These features indicate that the 
use of RNAi could cause antitumor effects. siRNA could be, 
for example, a hope for patients with brain tumors. The most 
devastating primary human brain tumor is Glioblastoma mul-
tiforme (GBM). The current therapy for GBM is based on 
surgery followed by radiotherapy and chemotherapy [115]. 
Unfortunately, mediana patients survival is approximately 
only 8 months. Glioma cell invasion mechanism is based on 
the attachment of tumor cells to extracellular matrix, its deg-
radation and penetration into adjacent brain structures [116]. 
RNAi against tenascin-C (extracellular matrix protein, highly 
expressed in cancer tissues and probably responsible for in-
vasiveness of glioma cells [117]) was injected into the post-
operative area of the patient’s brain.  
Positive effects of RNAi applications in patients with a 
brain tumor on survivals compared to the bronchytherapy 
was characterized by The Karnofsky Performance Scale In-
dex (KPS). KPS allows the description of the patients func-
tional impairment. This index can be used to compare effec-
tiveness of different therapies and to assess the prognosis in 
individual patients [118]. Because the most malignant glio-
mas are known to be chemo- and radiotherapy resistant due 
to the inhibition of the apoptotic pathway, recently discov-
ered RNA interference phenomenon may be the method of 
choice suitable for such treatment [89].  
Below we present other anti-cancer molecules which use 
the RNA interference mechanism and are under clinical tri-
als. 
CALAA-01 
Ribonucleotide reductase (RR) catalyzes the conversion 
of ribonucleoside 5 -diphosphates into their corresponding 2 
-deoxyribonucleotides and is a rate-limiting step in the path-
way for the production of 2 -deoxyribonucleoside 5-
triphosphates that are necessary for DNA replication. Human 
RR consists of two subunits, RRM1 and RRM2, and the ex-
pression of both proteins is required for enzymatic activity 
[119]. RR has long been an important target for controlling 
pathologies that depend on DNA replication. Moreover, in-
hibition of RR activity has been tested as potential anticancer 
therapy. 
siRNA against RRM2 has antiproliferative activity in 
many cancer types [120]. Whang et al. have used siRNA 
against RRM2 to enhance pancreatic adenocarcinoma che-
mosensitivity to gemcitabine and retrovirally expressed 
siRNA against RRM2 to attenuate pancreatic adenocarci-
noma cellular invasiveness and diminish its gemcitabine 
resistance [121]. These reports provide motivation for study 
of siRNA-mediated inhibition of RRM2 because potent se-
quences could provide for specific and effective therapies.  
The delivery of siRNA into the human body is problem-
atic for a long time. Particles which are designed to act in 
living organisms have to be no-antigenic which will allow 
repeat dosing. Nucleic acid should be encapsulated to protect 
its structure from nucleases and Toll-like receptors on cell 
surface. Particle size should be larger than 10 nm but not 
larger than 75 ± 25 nm (to minimize renal clearance) [122]. 
Because of these, as well as many other restrictions, until 
2008 there was no particle in clinics which was able to de-
liver siRNA for cancer. In 2008 Calando Pharmaceuticals 
was the first to enter the clinic with their target delivery of 
siRNA for cancers – CALAA-01 [123]. The exact nature of 
CALAA-01 has not been reported, but it is known that this 
nanoparticle consists of cyclodextrin-containing polymer 
(CDP), an adamantane -PEG conjugate (AD-PEG) and ada-
mantane conjugate of PEG that has human transferrin (Tf) 
conjugated at the end opposite to the adamantane (Tf-PEG-
AD) combined with siRNA against RRM2. The transferrin 
on the nanoparticle is able to bind to transferrin receptors 
(TfRs) which are a cell surface protein overexpressed on 
various cancer cell types. The nanoparticles can be internal-
ized via receptor-mediated endocytosis. As mentioned previ-
ously, siRNA against RRM2 has antiproliferative activity in 
many cancer types [120]. The CALAA-01 siRNA is pro-
tected from nuclease degradation within a stabilized 
nanoparticle targeted to tumor cells. CALAA-01 is now in 
the Phase I trial. According to the service of the U.S. Na-
tional Institutes of Health [124] this Phase will: 
• Determine the safety, toxicity, and the maximum toler-
ated dose (MTD) of CALAA-01 when administered in-
travenously to patients with relapsed or refractory can-
cer. 
• Characterize the pharmacokinetics (PK) of CALAA-01 
after intravenous administration. 
• Provide preliminary evidence of efficacy of intravenous 
CALAA-01 by evaluating tumor response. 
• Recommend a dose of intravenous CALAA-01 for fu-
ture clinical studies. 
• Evaluate immune response, by measuring antibody and 
cytokine levels, and the effect of intravenous CALAA-
01 on complement. 
The estimated study completion date was December 
2012, but unfortunately no study results had been published 
before this review was completed. 
Atu027 
Another interesting agent against cancer was designed by 
Silence Therapeutics - one of the leading companies dealing 
with the use of RNA interference for the therapeutic pur-
poses. The name of the molecule, which is a lipoplex con-
taining siRNA, is Atu027 [125]. It was designed to silence 
gene expression of protein kinase N3 (PKN3) in the vascular 
endothelium during the therapy of solid tumors.  
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PKN3 is involved in signal transduction in the PI3K 
pathway which regulates a diverse set of cellular responses 
including growth, development, survival, motility, adhesion, 
immune cell function and glucose transport. PI3K is only 
transiently activated after growth factor stimulation of nor-
mal cells, and is rapidly turned off through tumor suppressor 
PTEN function. Excessive, chronic activation of this path-
way is observed in many types of cancer and appears to be 
involved in the process of metastasis [126]. A number of 
kinases and other signaling molecules, which mediate PI3K-
regulated events, represent candidate cancer therapy targets. 
However, most of these proteins act rather upstream in the 
PI3K signaling cascade and regulate multiple functions in 
normal cells. Because of this - their inhibition is likely to 
cause side effects. Leenders et al. identified and validated 
PKN3, a barely characterized protein kinase C-related mole-
cule, as a novel effector mediating malignant cell growth 
downstream of activated PI3K [127]. Preclinical studies 
demonstrated that Atu027, which targets PKN3 gene expres-
sion in vascular endothelium, is able to significantly inhibit 
the PKN3 pathway, tumor growth and metastasis. Recently, 
PKN3 has also been considered as a suitable therapeutic tar-
get for modulating tumor-associated angiogenesis, because 
analysis with Atu027 in cultured primary endothelial cells 
revealed an essential role of PKN3 for endothelial tube for-
mation and migration [125]. Moreover, tests with Atu027 
showed no interferon response or activation of cytokines, 
which is a frequent problem occurring when siRNA is ad-
ministered. Probably, closing the siRNA in lipoplex ensured 
the high safety of this drug [128].  
In the completed Phase I, the aim of which was to find 
the correct dose, it was shown that Atu027 is well tolerated 
and so far no dose dependent toxicities have been observed. 
Plasma samples of the patients showed dose-dependent in-
crease in siRNA antisense strand concentrations [128]. 
Therefore undoubtedly, Atu027 is a novel, promising inves-
tigational therapeutic agent in anticancer therapy. 
ALN-VSP02 
VEGF and kinesin spindle protein (KSP) are up-
regulated in many tumor cells and play an important role in 
tumor proliferation and survival. Because we have men-
tioned VEGF before, here we will only mention KSP. This 
motor protein has an exclusive and essential role in mitosis. 
It is required early in mitosis to separate the centrosomes of 
the emerging spindle poles, thus driving establishment of a 
bipolar mitotic spindle. 
Failure to establish a bipolar spindle results in a mitotic 
arrest, after which cells may experience a variety of fates, 
including abnormal exit from mitosis, resumption of the cell 
cycle, and apoptosis [129]. Inhibition of KSP results in mi-
totic arrest characterized by an abnormal mitotic spindle. The 
essential role of KSP in cell cycle makes it a target of intense 
research for the development of novel anticancer therapeu-
tics.  
ALN-VSP02 is a first dual-targeted RNAi drug - contains 
two siRNA: anti mRNA for KSP (anti-proliferative) and anti 
mRNA for VEGF (anti-angiogenic mechanism). Preventing 
translation of mRNA for these proteins may result in inhibi-
tion of tumor cells growth. In ALN-VSP02 therapeutic a 
SNALP (solid nucleic acid lipid particle) formulation was 
used. The Phase I clinical trial using ALN-VSP02 against 
hepatocellular carcinoma, which is the most common cancer 
worldwide, has been completed. Results were presented in 
June 2012. These data included safety and tolerability of 
multiple doses of ALN-VSP02, as well as evidence for anti-
tumor activity in this very advanced, heavily pre-treated can-
cer patient population. It showed that multiple patients 
achieved stable disease or better, including a patient with 
endometrial cancer metastatic to the liver who achieved a 
complete response [104]. 
siRNA-EphA2-DOPC 
Processes like metastasis, proliferation and angiogenesis 
are crucial to malignant progression. Receptor tyrosine 
kinase (EphA2) was shown to be very important in those 
processes. EphA2 is expressed at low levels in adult epithe-
lial cells and can negatively regulate cellular growth and 
migration. However, over-expression of this receptor is pre-
sent in many human cancers, and it may be involved in con-
trolling the proliferation, metastasis, and apoptosis of tumor 
cells. There are studies showing that a high level of EphA2 is 
often associated with poor prognostic features [130-133]. 
Downregulation of the receptor has been shown to decrease 
tumor growth and prolong survival in multiple preclinical 
models of ovarian, breast and pancreatic cancers. In ovarian 
cancer EphA2 is over-expressed in more than 75% of cases. 
Moreover, EphA2 seems to be an attractive target because of 
its low expression in normal adult tissue. In siRNA-EphA2-
DOPC siRNA is incorporated in the neutral liposome - 1,2-
dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC) what 
allows intra-tumor delivery. The clinical study started in 
May 2012 [134]. The goal of this clinical research is to learn 
about the safety of siRNA-EphA2-DOPC when given to pa-
tients with advanced, recurrent cancer. Researchers also want 
to learn the highest tolerable dose of this drug that can be 
given. The estimated primary completion date is March 2018 
[124]. 
TKM-PLK1 
PLK1 is a cell cycle-regulated kinase whose expression 
peaks during G2M Phase of the cell cycle and transiently 
associates with the spindle apparatus and the centromere 
region of mitotic chromosomes. It controls entry into mitosis 
and regulates the spindle checkpoint. It is often deregulated 
and overexpressed in tumor cells. RNAi-mediated depletion 
of PLK1 mRNA can lead to cell cycle arrest, growth inhibi-
tion and apoptosis in cancer cells. It is known that the 
nanoparticles carrying siRNA targeting the Plk1 gene can 
induce remarkable apoptosis in both HepG2 and MDA-MB-
435s cancer cells. Systemic delivery of specific siRNA by 
nanoparticles significantly inhibited luciferase expression in 
an orthotopic murine liver cancer model and suppressed tu-
mor growth in a MDA-MB-435s murine xenograft model, 
suggesting its therapeutic promise in disease treatment [135]. 
In June 2012 a new drug, TKM-PLK1, was introduced to the 
clinical study. The study is designed to determine the safety, 
tolerability of TKM-PLK1 in adult patients with solid tumors 
or lymphomas that are refractory to standard therapy or for 
whom there is no standard therapy. The drug was given di-
rectly into the cancer blood supply in the liver circulation. It 
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contains siRNA against Plk1 gene and there is evidence that 
it should cause tumors to shrink, which would help people to 
live longer or would made tumors easy to remove by surgery 
[136]. 
SPC2996 
In cancer the apoptosis cell-division ratio is altered. Bcl-2 
is an apoptosis suppressor protein, which has the ability to 
extend the lifespan of the cell. It is known that the expression 
of Bcl-2 in malignant tumors is higher than in normal cells 
[137, 138]. SPC2996 is a novel antisense molecule against 
chronic lymphocytic leukemia (CLL), which is the most 
common leukemia in adults in Western Europe and North 
America [139]. The drug binds with high potency to the 
messenger RNA for Bcl-2 and destroys it, resulting in a re-
duction in Bcl-2 protein concentration. The Phase II study 
for this drug was completed. The purpose of this study was 
to determine whether SPC2996 is effective and safe in the 
treatment of CLL. No study results had been published be-
fore this review was completed [124].  
FANG
TM
 
Often in cancer therapy RNAi molecules are combined 
with other agents. In FANGTM Vaccine bifunctional short 
hairpin RNAi (bi-shRNA) was combined with granulocyte-
macrophage colony-stimulating factor (GMCSF). The 
GMCSF protein is a potent stimulator of the immune system, 
recruiting and activating antigen presenting cells at the site 
of intradermal injection thereby promoting antigen presenta-
tion. bi-shRNA was developed to exploit both the cleavage 
and translational inhibition mechanisms of RNAi. Such 
molecules are able to induce RNase-H like cleavage and 
non-cleavage mediated degradation of the target mRNA. The 
furin bifunctional shRNA blocks furin protein production at 
the post transcriptional and translational levels. This de-
creases the conversion of the proforms TGF 1 and TGF 2 
proteins. Also, reduced furin protein levels have a negative 
feedback inhibition on TGF 1 and TGF 2 gene expressions, 
decreasing the levels of their mRNAs. The resulting decrease 
in TGF 1 and TGF 2 proteins reduces the local immuno-
suppression they cause and promotes tumor surface antigen 
and MHC protein display. Such interference downregulates 
endogenous TGF 1 which reduces the cytokine-associated 
immune suppression that is well documented in cancer pa-
tients. Using bi-shRNA - instead of siRNA or miRNA - in-
creases the efficacy of gene silencing [140]. There are four 
FANG vaccine related clinical trials: 
1. A Phase I Trial of FANG™ Vaccine for advanced 
solid tumors. This safety study is currently recruiting 
participants. Estimated study completion date is De-
cember 2014.  
2. A Phase II Trial of FANG™ Vaccine for high risk 
stage IIIc ovarian cancer. This safety and efficacy 
study is currently recruiting participants. Trial end-
points include time to recurrence documentation of 
immune responses, correlation of immune response 
and clinical effect. Estimated study completion date is 
January 2016.  
3. A Phase II Trial of FANG™ Vaccine for patients with 
advanced melanoma. This is a safety and efficacy 
study of intradermal autologous FANG cancer vaccine 
in patients with stages IIIc and IV melanoma with bi-
opsy accessible lesions to document blood and intra-
tumoral immune responses and assess correlation with 
survival. This study is currently recruiting participants. 
Estimated study completion date is December 2013. 
The investigators have completed the Phase I assess-
ment of FANG vaccine. The study was done in 27 ad-
vanced solid tumor patients group. None of these pa-
tients have experienced significant adverse effects fol-
lowing 131 vaccinations, including 4 patients with 
melanoma. Plasmid functionality, immune biomarker 
response, and preliminary evidence of anticancer activ-
ity have been observed. 
4. A Phase II Trial of FANG™ Vaccine for patients with 
colorectal cancer. This efficacy study is currently re-
cruiting participants. Estimated study completion date 
is January 2015. The investigators have completed the 
Phase I assessment of FANG vaccine in 30 advanced 
solid tumor patients who have not experienced any 
significant adverse effects following 144 vaccinations, 
including 6 patients with colorectal carcinoma. 
siG12D LODER 
KRAS is a member of the small GTPase superfamily. In 
over 90% of human pancreatic ductal adenocarcinomas this 
protein is mutated. This mutation can be associated with tu-
mor cell proliferation and reduced survival. siG12D 
LODER contains siRNA for the siG12D (mutated KRAS 
oncogen). In this drug the biodegradable polymer matrix was 
used. This matrix allows local deliver of siRNA into the pan-
creatic tumor not at once, but over a sustained period of 
about 8 weeks [141]. siG12D LODER has been studied in 
the escalating dose Phase I study of 12 patients, and the re-
sults showed a high safety and tolerability profile. In Phase II 
study a single dose 3,000 g will be administered to patients 
with unresectable locally advanced pancreatic cancer 
(LAPC) combined with chemotherapy treatment (Gemcit-
abine or FOLFIRINOX). This will be the first study to assess 
the response rate of the siG12D LODER in patients with 
unresectable LAPC. 
CONCLUSIONS 
The discovery of RNAi has brought many changes to 
modern physiology and medicine. It opened up new possi-
bilities for the study of proteins and genes functions in dif-
ferent organisms. But probably the most important fact is 
that this discovery puts a new weapon in the hands of spe-
cialists in the fight against diseases with such different sur-
faces like AMD, RSV, HIV, hepatitis C or Huntington dis-
ease, and, as demonstrated in the studies cited, also in the 
fight against various types of cancers. 
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ABBREVIATIONS 
AAV = Adeno-Associated Virus 
AD-PEG = An Adamantane -PEG Conjugate 
AMD = Age-Related Macular Degeneration 
AON = Antisense Oligonucleotides 
ATTR = Transthyretin-Mediated Amyloidosis 
bi-shRNA = Bifunctional Short Hairpin RNAi 
BOS = Bronchiolitis Obliterans Syndrome 
CDP = Cyclodextrin-Containing Polymer 
CLL = Chronic Lymphocytic Leukemia 
CTGF = Connective Tissue Growth Factor 
DME = Diabetic Macular Edema 
DOPC = 1,2-dioleoyl-sn-glycero-3-Phosphatidyl 
choline 
dsRNA = Double-Stranded RNA 
FAP = Familial Adenomatous Polyposis 
Gag = Glycosaminoglycans 
GBM = Glioblastoma Multiforme 
GMCSF = Granulocyte-Macrophage Colony-Stimula 
ting Factor 
HIF-1 = Hypoxia-Induced Factor 
HUVECs = Human Umbilical Vein Endothelial Cells 
IAP = Inhibitors of Apoptosis Protein 
IOP = Intraocular Pressure 
KSP = Kinesin Spindle Protein 
LAPC = Locally Advanced Pancreatic Cancer 
LNP = Lipid Nanoparticle 
MPS = Mucopolisaccharidoses 
NSCLC = Non-Small-Cell-Lung Cancer 
Nrf2 = Nuclear Factor (erythroid-derived 2)-like 2 
PC = Pachyonychia Congenital 
PCSK9 = The Gene Proprotein Convertase Sub-
tilisn/kexin Type 9 
PDAC = Pancreatic Ductal Adenocarcinoma 
PKN3 = Protein Kinase N3 
POAG = Primary Open Angle Glaucoma 
PTGS = Post-Transcriptional Gene Silencing 
RISC = RNA-Induced Silencing Complex 
RNAi = RNA Interference 
ROS = Reactive Oxygen Species 
RR = Ribonucleotide Reductase 
RRM2 = Ribonucleotide Reductase Subunit 
RSV = Respiratory Syncytial Virus 
SDT = Substrate Deprivation Therapy 
shRNA = Short Hairpin RNA 
siRNA = Small Interfering RNA 
SNALP = Solid Nucleic Acid Lipid Particles 
Tf-PEG-AD = Adamantane Conjugate of PEG that has 
Human Transferrin (Tf) Conjugated At the 
End Opposite to the Adamantane 
TTR = Transthyretin 
VEGF = Vascular Endothelial Growth Factor 
ZEBOV = Zaire Species of Ebola Virus 
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